While these analyses provide valuable insights into the general effectiveness of GLP-1 receptor agonists, they do not allow for a direct comparative assessment between different agents within this drug class
doi:10.1136/jim-2021-001952 48
Last reviewed: June 17, 2026 Last updated: June 17, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
While greater magnitudes of weight reduction can potentially lead to significant improvements in cardiovascular risk factors in some patients, not all patients will require higher magnitudes of weight reduction
In a sealed order, Judge Mark Pittman upheld the FDAs prior declaration that Lillys tirzepatide was no longer in shortage